Sitravatinib

Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases.^[1]

Sitravatinib

Clinical data
ATC code	L01EX26 (WHO)
Identifiers
IUPAC name N-(3-Fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
CAS Number	1123837-84-2
ChemSpider	52083477
UNII	CWG62Q1VTB
KEGG	D11140
CompTox Dashboard (EPA)	DTXSID801100124
Chemical and physical data
Formula	C33H29F2N5O4S
Molar mass	629.68 g·mol−1
3D model (JSmol)	Interactive image
SMILES COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
InChI InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42) Key:WLAVZAAODLTUSW-UHFFFAOYSA-N

Sitravatinib is being developed by Mirati Therapeutics.^[2]

Ongoing phase II trials include a trial for liposarcoma,^[3] a combination trial for non-small cell lung cancer,^[4] and a combination trial with nivolumab for renal cell carcinoma.^[5] Sitravatinib is being evaluated in ongoing trials in patients with advanced non-small cell lung cancer, including in a combination trial with nivolumab in those who are resistant to checkpoint inhibitor therapy, and certain patients who are naïve to checkpoint inhibitor therapy.^[6]